[go: up one dir, main page]

WO2005054849A3 - Diagnostic et therapeutique pour des maladies associees au recepteur mc5 couple a une proteine g - Google Patents

Diagnostic et therapeutique pour des maladies associees au recepteur mc5 couple a une proteine g Download PDF

Info

Publication number
WO2005054849A3
WO2005054849A3 PCT/EP2004/013277 EP2004013277W WO2005054849A3 WO 2005054849 A3 WO2005054849 A3 WO 2005054849A3 EP 2004013277 W EP2004013277 W EP 2004013277W WO 2005054849 A3 WO2005054849 A3 WO 2005054849A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
mc5r
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/013277
Other languages
English (en)
Other versions
WO2005054849A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005054849A2 publication Critical patent/WO2005054849A2/fr
Publication of WO2005054849A3 publication Critical patent/WO2005054849A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à un récepteur MC5 humain associé aux troubles cardio-vasculaires, aux maladies gastro-intestinales et hépatiques, aux maladies inflammatoires, aux maladies métaboliques, aux troubles hématologiques, aux maladies respiratoires, aux troubles neurologiques, aux troubles urologiques et aux troubles cancéreux. L'invention a également trait à des dosages pour l'identification de composés utiles dans le traitement ou la prévention de troubles cardio-vasculaires, de maladies gastro-intestinales et hépatiques, de maladies inflammatoires, de maladies métaboliques, de troubles hématologiques, de maladies respiratoires, de troubles neurologiques, de troubles urologiques et de troubles cancéreux. L'invention a trait en outre à des composés de liaison à et/ou d'activation ou d'inhibition de l'activité du récepteur MC5 ainsi qu'à des compositions pharmaceutiques comportant de tels composés.
PCT/EP2004/013277 2003-12-06 2004-11-23 Diagnostic et therapeutique pour des maladies associees au recepteur mc5 couple a une proteine g WO2005054849A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03028032.5 2003-12-06
EP03028032 2003-12-06

Publications (2)

Publication Number Publication Date
WO2005054849A2 WO2005054849A2 (fr) 2005-06-16
WO2005054849A3 true WO2005054849A3 (fr) 2005-08-11

Family

ID=34639278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/013277 WO2005054849A2 (fr) 2003-12-06 2004-11-23 Diagnostic et therapeutique pour des maladies associees au recepteur mc5 couple a une proteine g

Country Status (1)

Country Link
WO (1) WO2005054849A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028002A1 (fr) * 1998-11-09 2000-05-18 Merck & Co., Inc. Molecules d'adn codant la proteine de recepteur de melanocortine 5 provenant de singe rhesus
WO2003040117A1 (fr) * 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical Corporation Nouveaux derives de 1,2,4-thiadiazole comme modulateurs du recepteur de la melanocortine
US20030110518A1 (en) * 2001-09-28 2003-06-12 Houseknecht Karen L. Melanocortin-5 receptor sequences and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028002A1 (fr) * 1998-11-09 2000-05-18 Merck & Co., Inc. Molecules d'adn codant la proteine de recepteur de melanocortine 5 provenant de singe rhesus
US20030110518A1 (en) * 2001-09-28 2003-06-12 Houseknecht Karen L. Melanocortin-5 receptor sequences and uses thereof
WO2003040117A1 (fr) * 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical Corporation Nouveaux derives de 1,2,4-thiadiazole comme modulateurs du recepteur de la melanocortine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL: "Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 91, no. 6, 12 December 1997 (1997-12-12), pages 789 - 798, XP002083691, ISSN: 0092-8674 *
GRIECO P ET AL: "Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4, and 5.", JOURNAL OF PEPTIDE RESEARCH, vol. 62, no. 5, November 2003 (2003-11-01), pages 199 - 206, XP002317829, ISSN: 1397-002X *
VAN DER KRAAN MANOU ET AL: "Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands", ENDOCRINOLOGY, vol. 13, no. 5, May 1998 (1998-05-01), pages 2348 - 2355, XP002317830, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2005054849A2 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005106492A3 (fr) Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005103702A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2005054849A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur mc5 couple a une proteine g
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2004086052A3 (fr) Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2005003762A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 2 couple a la proteine g specifique aux neurones sensoriels (snsr2)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005059561A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 31 (gpr31)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 04819612

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 04819612

Country of ref document: EP

Kind code of ref document: A2